HERMAB - 150MG (Applepharmaceutical)

HERMAB - 150MG (Applepharmaceutical)

DESCRIPTION :

hermab 150mg  is a group of medicines which belongs to anti neoplastic medication.Hermab 150 mg injection is a chemotherapy drug. It is recommended that hermab 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES
The injection hermab 150mg  is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.

hermab 150mg  acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals,hermab 150mg  can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting hermab 150mg  receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.

DOSAGE :

The injection Hermab should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine
Adjuvant treatment, breast cancer:
The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV(intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hermab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.
The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

PRECAUTION :

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hermab 150mg treatment.
Hermab 150mg interaction with anthracycline after ending of Hermab 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hermab 150mg, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 150mg diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE :

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

hermab 150mg

SIDE EFFECTS :

Common side effects:
Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain

Serious side effects:

Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing


for more information please click this link below - Hermab 150mg , Hermab 150 mg injection

Contact Details :

    Phone : +91-9987711567 

    Email : applepharmaceutical@gmail.com

    Email : info@myapplepharma.com

    0091-9987711567

    applepharmaceuticals